Multiple and central nervous system extranodal involvement predict poor prognosis in R/R DLBCL following CD19 CAR-T therapy.
BACKGROUND CD19 chimeric antigen receptor T-cell (CAR-T) therapy has achieved remarkable results in treating patients with refractory or relapsed diffuse large B-cell lymphoma (R/R DLBCL). Nevertheless, certain limitations still persist. This study focuses on the impact of extranodal involvement before treatment on the...